Patents by Inventor Matthew D. Cheeseman

Matthew D. Cheeseman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Deuterated N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide
    Patent number: 11814370
    Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: November 14, 2023
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Keith Jones, Matthew D. Cheeseman, A. Elisa Pasqua, Michael J. Tucker
  • Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1
    Patent number: 11787786
    Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: October 17, 2023
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew D. Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1
    Publication number: 20220220097
    Abstract: The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: August 19, 2021
    Publication date: July 14, 2022
    Inventors: Keith Jones, Carl Rye, Nicola Chessum, Matthew D. Cheeseman, Adele E. Pasqua, Kurt G. Pike, Paul F. Faulder
  • DEUTERATED N-(5-(2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDO)-2-FLUOROPHENYL)-2-((4-ETHYLPIPERAZIN-1-YL)METHYL)QUINOLINE-6-CARBOXAMIDE
    Publication number: 20200039965
    Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.
    Type: Application
    Filed: October 6, 2017
    Publication date: February 6, 2020
    Inventors: Keith Jones, Matthew D. Cheeseman, A. Elisa Pasqua, Michael J. Tucker